Investment Rating - The report does not explicitly provide an investment rating for the biosimilar industry or ophthalmology sector Core Insights - The biosimilar market is expected to grow significantly, particularly with the introduction of aflibercept biosimilars, which could lead to substantial cost savings and improved patient outcomes in ophthalmology [3][23][24] - The report emphasizes the importance of addressing barriers to biosimilar adoption, including stakeholder education and awareness, to unlock the full potential of biosimilars in the healthcare system [11][18][67] Overview - Biologic medicines account for over 40% of total pharmaceutical spending in the EU, up from 28% in 2014, highlighting the financial pressures on healthcare systems [9][25] - Biosimilars currently represent only 5% of biologics spending, yet they have contributed €75 billion in cumulative savings in Europe and enabled over 9 billion treatment days [9][30] - The upcoming loss of exclusivity for 69 biologics between 2024 and 2030 presents a significant opportunity for biosimilars, with an estimated pre-expiry value of €28 billion [11][35] Ophthalmology Treatment Landscape and Challenges - The prevalence of age-related macular degeneration (AMD) is projected to rise by 15% by 2050, affecting approximately 67 million Europeans in 2022 [12][45] - Current treatment for retinal diseases is dominated by intravitreal anti-VEGF therapies, which require frequent injections and follow-ups, leading to capacity constraints in ophthalmology systems across Europe [13][16] - The introduction of biosimilars could alleviate capacity pressures by generating cost savings that can be reinvested into healthcare systems [14][58] Stakeholder Perspectives on Biosimilars and Barriers to Adoption - Interviews with 142 stakeholders revealed low confidence and limited use of biosimilars in ophthalmology, with confidence scores ranging from 2/7 in France, Germany, and Spain to 5.5/7 in the UK [15][61] - Key barriers to adoption include limited stakeholder experience, concerns about comparability, and fragmented decision-making processes [17][67] - Education campaigns targeting clinicians and other stakeholders are essential to build trust and address misconceptions about biosimilars [18][19] Overcoming Barriers to Biosimilar Adoption - Comprehensive education campaigns should focus on the principles of biosimilarity, regulatory rigor, and clinical comparability to enhance clinician confidence [18][19] - Strengthening the evidence base with accessible data on clinical performance and cost-effectiveness is critical for informed decision-making [19][20] - Reinvesting savings from biosimilars into ophthalmology services can incentivize providers and improve access to care [21][24]